Recombinant BCG coexpressing Ag85B, ESAT-6 and Rv3620c elicits specific Th1 immune responses in C57BL/6 mice

Microbial Pathogenesis

Volumn 69-70, Issue 1, 2014, Pages 53-59

  Yang, Enzhuo ^a   Lu, Yunzhi ^a   Xu, Ying ^a   Liang, Qing ^b   Wang, Chao ^a   Wang, Honghai ^a   Shen, Hongbo ^a  

^a FUDAN UNIVERSITY   (China)

^b Rizhao Polytechnic   (China)

Author keywords

Cytokines; Mycobacterium tuberculosis; RBCG; Th1; Vaccine

Indexed keywords

AG85B ESAT 6 RV3620C PROTEIN; BCG VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2B; INTERLEUKIN 10; RECOMBINANT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACYLTRANSFERASE; ANTIGEN 85B, MYCOBACTERIUM TUBERCULOSIS; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CYTOKINE; ESAT-6 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; IMMUNOGLOBULIN G; RV3620C PROTEIN, MYCOBACTERIUM TUBERCULOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; INFECTION PREVENTION; LYMPHOCYTE PROLIFERATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TH1 CELL; TH2 CELL; TUBERCULOSIS; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CELL PROLIFERATION; GENETICS; IMMUNOLOGY; MYCOBACTERIUM BOVIS; SECRETION (PROCESS);

ACYLTRANSFERASES; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; IMMUNOGLOBULIN G; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; RECOMBINANT FUSION PROTEINS; TH1 CELLS; VACCINES, SYNTHETIC;

EID: 84899118196     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2014.03.011     Document Type: Article

References (34)

1. The Henry J Kaiser Family Foundation. The U.S Government and Global Tuberculosis, 2014. http://kff.org/global-health-policy/fact-sheet/the-u-s-government-and-global-tuberculosis/.
2. Pablos-Méndez A., Raviglione M.C., Laszlo A., Binkin N., Rieder H.L., Bustreo F., et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. NEngl J Med 1998, 338:1641-1649.
3. Norazmi M.N., Mustaffa M. Approaches towards the development of a vaccine against tuberculosis: recombinant BCG and DNA vaccine. Tuberculosis 2004, 84:102-109.
4. Bloom B.R., Fine P.E.M. The BCG experience: implications for future vaccines against tuberculosis. Tuberculosis: pathogenesis, protection, and control 1994, 531-557. ASM Press, Washington, DC. B.R. Bloom (Ed.).
5. Fine P.E., Rodrigues L.C. Modern vaccines: mycobacterial diseases. Lancet 1990, 335:1016-1020.
6. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346:1339-1345.
7. Wiker H.G., Harboe M. The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 1992, 56:648-661.
8. Horwitz M.A., Harth G., Dillon B.J., Masleša-Galić S. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000, 97:13853-13858.
9. Horwitz M.A., Harth G. Anew vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003, 71:1672-1679.
10. Brandt L., Elhay M., Rosenkrands I., Lindblad E.B., Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000, 68:791-795.
11. Andersen P., Andersen A.B., Sorensen A.L., Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. JImmunol 1995, 154:3359-3372.
12. Mahmood A., Srivastava S., Tripathi S., Aesari M.A., Owais M., Arora A. Molecular characterization of secretory proteins Rv3619c and Rv3620c from Mycobacterium tuberculosis H37Rv. FEBS J 2011, 278(2):341-353.
13. Mattow J., Schaible U.E., Schmidt F., Hagens K., Siejak F., Brestrich G., et al. Comparative proteome analysis of culture supernatant proteins from virulent Mycobacterium tuberculosis H37Rv and attenuated M. bovis BCG Copenhagen. Electrophoresis 2003, 24:3405-3420.
14. He X.Y., Zhuang Y.H., Zhang X.G., Li G.L. Comparative proteome analysis of culture supernatant proteins of Mycobacterium tuberculosis H37Rv and H37Ra. Microbes Infect 2003, 5:851-856.
15. Brodin P., Rosenkrands I., Andersen P., Cole S.T., Brosch R. ESAT-6 proteins: protective antigens and virulence factors?. Trends Microbiol 2004, 12:500-508.
16. Bertholet S., Ireton G.C., Kahn M., Guderian J., Mohamath R., Stride N., et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. JImmunol 2008, 181:7948-7957.
17. Shen H., Wang C., Yang E., Xu Y., Liu W., Yan J., et al. Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-α induces significantly enhanced cellular immune and antibody responses in C57BL/6 mice. Microbiol Immunol 2010, 54:435-441.
18. Bao L., Chen W., Zhang H., Wang X. Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis bacille Calmette-Guérin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis. Infect Immun 2003, 71:1656-1661.
19. Martin R.M., Lew A.M. Is IgG2a a good Th1 marker in mice?. Immunol Today 1998, 19:49.
20. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. JImmunol 1986, 136:2348-2357.
21. Derrick S.C., Yang A.L., Morris S.L. Apolyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacerium tuberculosis and boosts BCG-induced protective immunity. Vaccine 2004, 23:780-788.
22. Chensue SW, Warmington KS, Ruth JH, Lincoln P, Kunkel SL. Cytokine function during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Local and regional participation of IFN-gamma, IL-10, and TNF. J Immunol 154: 5969-5976.Pubmed Partial Year.
23. Young S.L., O'Donnell M.A., Buchan G.S. IL-2-secreting recombinant bacillus Calmette Guerin can overcome a Type 2 immune response and corticosteroid-induced immunosuppression to elicit a Type 1 immune response. Int Immunol 2002, 14:793-800.
24. Caruso A.M., Serbina N., Klein E., Triebold K., Bloom B.R., Flynn J.L. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. JImmunol 1999, 162:5407-5416.
25. Smith S.M., Malin A.S., Pauline T., Atkinson S.E., Huygen K., Dockrell H.M. Characterization of human Mycobacterium bovis bacillus Calmette-Guerin-reactive CD8+ T cells. Infect Immun 1999, 67:5223-5230.
26. Serbina N.V., Flynn J.L. Early emergence of CD8+ T cells primed for production of type 1 cytokines in the lungs of Mycobacterium tuberculosis-infected mice. Infect Immun 1999, 67:3980-3988.
27. Fine P.E. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 1989, 11(Suppl 2):S353-S359.
28. Flynn J.L., Goldstein M.M., Triebold K.J., Koller B., Bloom B.R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992, 89:12013-12017.
29. + T cell lines. Eur J Immunol 1988, 18:59-66.
30. + T-lymphocytes in intracellular microbial infections. Immunol Today 1988, 9:168-174.
31. Ordway D., Martins M., Costa L., Freire M., Arroz M., Dockrell H., et al. IncreasedIL-4 production in response to virulent Mycobacerium tuberculosis in tuberculosis patients with advanced disease. Acta Med Port 2005, 18:27-36.
32. Neeraj D., Vivek R., Anil K.T. Skewing of the Th1/Th2 responses in mice due to variation in level of expression of an antigen in a recombinant BCG system. Immunol Lett 2003, 88:175-184.
33. Hovav A.-H., Mullerad J., Davidovitch L., Fishman Y., Bigi F., Cataldi A., et al. The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection. Infect Immun 2003, 71:3146-3154.
34. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.